581 related articles for article (PubMed ID: 33957995)
1. Current and emerging therapies for primary central nervous system lymphoma.
Yuan Y; Ding T; Wang S; Chen H; Mao Y; Chen T
Biomark Res; 2021 May; 9(1):32. PubMed ID: 33957995
[TBL] [Abstract][Full Text] [Related]
2. Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
Miyao K; Yokota H; Sakemura RL
Front Oncol; 2022; 12():1082235. PubMed ID: 36686821
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
4. A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy.
Mizuta R; Otani Y; Fujii K; Uneda A; Ishida J; Tanaka T; Ikegawa S; Fujii N; Maeda Y; Date I
NMC Case Rep J; 2022; 9():275-280. PubMed ID: 36238605
[TBL] [Abstract][Full Text] [Related]
5. Biology and treatment of primary central nervous system lymphoma.
Algazi AP; Kadoch C; Rubenstein JL
Neurotherapeutics; 2009 Jul; 6(3):587-97. PubMed ID: 19560747
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the management of primary central nervous system lymphoma.
Choi YS
Blood Res; 2020 Jul; 55(S1):S58-S62. PubMed ID: 32719178
[TBL] [Abstract][Full Text] [Related]
10. CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
Karschnia P; Blobner J; Teske N; Schöberl F; Fitzinger E; Dreyling M; Tonn JC; Thon N; Subklewe M; von Baumgarten L
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065471
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma.
Löw S; Han CH; Batchelor TT
Ther Adv Neurol Disord; 2018; 11():1756286418793562. PubMed ID: 30305848
[TBL] [Abstract][Full Text] [Related]
12. Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma.
Alcantara M; Fuentealba J; Soussain C
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680209
[TBL] [Abstract][Full Text] [Related]
13. How we treat primary central nervous system lymphoma.
Calimeri T; Steffanoni S; Gagliardi F; Chiara A; Ferreri AJM
ESMO Open; 2021 Aug; 6(4):100213. PubMed ID: 34271311
[TBL] [Abstract][Full Text] [Related]
14. [Primary central nervous system lymphoma: advances in treatment strategies].
Kondo E
Rinsho Ketsueki; 2020; 61(5):510-519. PubMed ID: 32507817
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of primary central nervous system lymphoma.
Han CH; Batchelor TT
Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
[TBL] [Abstract][Full Text] [Related]
16. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review.
Tsang M; Rubenstein JL; Pulczynski EJ
Ann Lymphoma; 2021 Sep; 5():. PubMed ID: 35106521
[TBL] [Abstract][Full Text] [Related]
18. Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.
Calimeri T; Steffanoni S; Foppoli M; Ponzoni M; Ferreri AJM
Expert Opin Ther Targets; 2021 Sep; 25(9):749-760. PubMed ID: 34606736
[No Abstract] [Full Text] [Related]
19. Recent advances and challenges in primary central nervous system lymphoma: a narrative review.
Ma L; Gong Q
Transl Cancer Res; 2023 May; 12(5):1335-1352. PubMed ID: 37304530
[TBL] [Abstract][Full Text] [Related]
20. Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies.
Holdhoff M; Wagner-Johnston N; Roschewski M
Onco Targets Ther; 2020; 13():8323-8335. PubMed ID: 32903865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
